Pricing Log in Create free account
Saturday 7 November 2026 Export RIGL’s income statement to Excel — free account

Rigel Pharmaceuticals, Inc.

RIGL Healthcare Biotechnology

Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024.

Revenue
+16.5%
EPS
−54.8%
Free cash flow
+43.9%
Total debt
−66.6%

Quarter to September 2026, against a year earlier

39.59 6.12 −13.39%
Market cap
$853.9M
P/E
2.4×
Fwd P/E
16.4×
Dividend yield
—
F-score
6/9
Altman Z
2.70
Beneish M
0.78
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.31
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 1 — — 1 1 — — — — —
Insider Ownership 3.47%

Capital & Financial Ratios $m

Size
Market Cap 853.86
Revenue ttm 288.21
Net income ttm 307.19
Free cash flow ttm 89.92
Net debt Q (99.30)
Valuation
P/E 2.35
Forward P/E 16.40
Price / sales 2.57
Forward P/S Powerpack
Price / FCF 37.96
Price / book 1.66
Financial health
Current ratio Q 2.39 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 66.56
Growth
Revenue growth Q +16.45% (above 0%: growing)
Operating income growth Q −39.81% (below 0%: shrinking)
EPS, this year −82.07% (below 0%: weak)
EPS, next year A +32.05% (at or above 15%: strong)
Revenue, next year A +3.88%
EPS, past 5 yrs —
EPS, next 5 yrs A +67.79% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 2.9×; over the ten years it ranged from 0.8× in 2022 to 44.9× in 2018.
P/S against its own 10 years 33.91%
10-year low 10-year high
P/B against its own 10 years 5.15%
10-year low 10-year high
EV/Sales against its own 10 years 38.42%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 57 77 155 99
Receivables 31 42 52 56
Inventory 6 6 12 16
Other — — — —
99 135 240 189
2023 2024 2025 Q'26
Payables 7 3 7 11
ST’ Debt — — — —
Other 19 38 44 —
53 63 99 79

Compound Annual Growth %

10y 5y 3y
Sales 26.12% 22.06% 34.76%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 15.66% 63.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.91 Actual 0.88

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.93 1.46 Beat by 0.53
Q4 FY25 1.33 1.14 Miss by 0.19
Q1 FY26 0.74 0.44 Miss by 0.30
Q2 FY26 0.91 0.88 Miss by 0.03
Q3 FY26 0.87 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.44 0.88 0.65 — —
’25 0.63 3.28 1.46 13.54 19.48
’24 (0.50) (0.06) 0.70 0.80 0.99
’23 (0.80) (0.40) (0.30) 0.04 (1.40)
’22 (1.60) (0.80) (1.10) 0.10 (3.40)
’21 2.20 (0.80) (1.20) (1.30) (1.10)
’20 1.30 (1.00) (0.80) (1.10) (1.80)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 59 79 81 — —
’25 53 102 69 70 294
’24 30 37 55 58 179
’23 26 27 28 36 117
’22 17 30 22 51 120
’21 81 26 22 20 149
’20 56 16 18 18 109
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 31 35 — —
’25 (1) 31 24 22 76
’24 (5) 0 22 15 31
’23 (4) 6 (1) (6) (6)
’22 (26) (13) (13) (22) (74)
’21 (20) 55 (10) (19) 6
’20 (3) (14) (19) (16) (52)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 (40) 35 — —
’25 (1) 31 24 22 76
’24 (5) 0 22 15 31
’23 (19) 6 (1) (6) (20)
’22 (26) (13) (13) (22) (73)
’21 (20) 55 (10) (19) 5
’20 (4) (14) (20) (16) (53)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 20 4 45 59 109 149 120 117 179 294 288 +34.5% 306 373 445 +14.8%
Gross margin, % 100.00 100.00 99.36 98.47 99.18 99.27 98.55 93.92 89.60 93.33 89.64 (6.7) pt
EBT (69) (78) (70) (67) (30) (17) (59) (25) 18 122 75 n/m
EBT margin, % (339.58) (1,739.34) (158.35) (112.83) (27.38) (11.60) (48.71) (21.47) 10.24 41.40 26.15 +381.0 pt
Net income (69) (78) (70) (67) (30) (18) (59) (25) 17 367 307 n/m
Per share, $
Per share, $ Revenue 2.16 0.36 2.77 3.54 6.44 8.75 7.05 6.72 10.20 16.36 15.40 +25.2%
Earnings (7.30) (6.20) (4.40) (4.00) (1.80) (1.10) (3.40) (1.40) 0.99 20.40 16.82 n/m
Cash flow (8.04) (6.14) (3.66) (2.48) (3.09) 0.34 (4.33) (0.33) 1.79 4.21 4.81 n/m
Capex (0.08) 0.05 (0.07) (0.09) (0.07) (0.04) 0.03 (0.85) (0.02) 0.00 0.00 n/m
Free cash flow (8.12) (6.09) (3.73) (2.57) (3.17) 0.31 (4.30) (1.18) 1.77 4.21 4.81 n/m
Book value 5.83 7.97 6.84 3.21 2.02 1.78 (0.80) (1.65) 0.19 21.76 23.79 +15.8%
Shares, m 9 13 16 17 17 17 17 17 18 18 18 +7.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 17.52 2.12 2.35 2.0
P/S 11.53 44.49 8.13 6.04 5.44 3.03 1.90 2.17 1.65 2.62 2.57 8.7
P/B 4.27 4.97 3.36 6.66 17.36 14.87 0.00 0.00 89.93 1.97 1.66 14.3
EV/Sales 7.87 34.22 5.31 4.55 5.09 2.32 1.74 2.13 1.51 2.17 2.28 6.7
EV/FCF (2.10) (5.00) (4.02) (6.28) (10.35) 66.04 (2.86) (12.18) 8.65 8.45 33.64 4.0
Cash, $m
Cash, $m Operating cash flow (76) (78) (59) (42) (52) 6 (74) (6) 31 76 90 n/m
Capex (1) 1 (1) (1) (1) (1) 0 (15) 0 — (71) (10.4%)
Free cash flow (77) (77) (60) (43) (53) 5 (73) (20) 31 76 90 n/m
Balance, $m
Balance, $m Working capital 54 99 109 61 48 91 51 46 72 141 110 +11.3%
Net debt (75) (116) (129) (88) (38) (105) (19) (5) (25) (132) (99) +6.6%
Shareholders’ equity 55 101 110 54 34 30 (14) (29) 3 391 445 +24.4%
Returns, %
Returns, % ROA (65.96) (79.08) (54.59) (46.67) (23.06) (12.90) (38.84) (19.95) 12.44 108.34 80.16 +174.3 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.28 13.69 +30.3 pt
ROE (94.55) (100.20) (66.96) (81.73) (67.72) (55.63) (699.05) 118.75 (137.92) 185.94 109.18 +280.5 pt
People
People Employees 77 103 158 163 169 165 155 147 164 174 — +9.5%
Revenue/emp, $m 0.26 0.04 0.28 0.36 0.64 0.90 0.78 0.80 1.09 1.69 — +22.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Rigel Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ORIC Oric Pharmaceuticals, Inc. $880.0M — (loss-making) — — n/m −3.42% (below 0%: shrinking) 0.00% 0.00% Compare
GLUE Monte Rosa Therapeutics, Inc. $874.5M — (loss-making) — (loss-making) +325.80% (above 0%: growing) n/m −142.63% (below 0%: shrinking) 100.00% (3.57%) Compare
PHAR Pharming Group N.V. Sponsored ADR $870.6M 34.2× — (loss-making) +20.86% (above 0%: growing) +190.91% (above 0%: growing) +0.42% (above 0%: growing) 86.90% 25.34% Compare
IVA Inventiva S.A. Sponsored ADR $867.9M — (loss-making) — (loss-making) −10.77% (below 0%: shrinking) n/m −20,989.22% (below 0%: shrinking) 0.00% 0.00% Compare
LTGO Latigo Biotherapeutics Inc $862.6M — — — n/m — — 0.00% Compare
ANRO Alto Neuroscience, Inc. $858.2M — (loss-making) — — n/m −43.41% (below 0%: shrinking) — 0.00% Compare
RIGL Rigel Pharmaceuticals, Inc. $853.9M 2.4× 16.4× +16.45% (above 0%: growing) −54.84% (below 0%: shrinking) +43.90% (above 0%: growing) 86.67% 21.15%
SNDX Syndax Pharmaceuticals, Inc. $843.6M — (loss-making) — (loss-making) +81.59% (above 0%: growing) n/m +61.43% (above 0%: growing) 83.20% (50.30%) Compare
AKTS Aktis Oncology, Inc. $826.0M — (loss-making) — (loss-making) — n/m −12.77% (below 0%: shrinking) 100.00% (853.99%) Compare
Median of peers $865.2M — — +51.23% — −12.77% 85.05% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 3 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 4.66m 8.68m 122.37
2024 3.00m 5.07m 48.06
2023 3.44m 2.06m 41.43
2022 2.86m 1.47m 42.86
2021 3.43m 866.86k 75.71

Ownership

Directors and executive officers, together 10.47%
BlackRock, Inc. 7.54%
Raul R. Rodriguez 5.97%
State Street Corporation 5.95%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Rigel Pharmaceuticals, Inc. (RIGL) Latest News

6 Nov

Impact 4 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · GuruFocus.com

5 Nov

Impact 3 · · PR Newswire

29 Oct

Impact 3 · · PR Newswire

23 Oct

Impact 4 · · Simply Wall St.

19 Oct

Impact 4 · · PR Newswire

13 Oct

Impact 3 · · Zacks

6 Oct

Impact 3 · · GlobeNewswire

16 Aug

Impact 4 ·

13 Aug

Impact 4 ·

11 Aug

Impact 3 · · The Motley Fool transcript

5 Aug

Impact 3 · · Moby transcript

4 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·

16 Jun

Impact 3 ·

23 May

Impact 3 · · Simply Wall St.

21 May

Impact 4 · · Simply Wall St.

15 May

Impact 4 · · Benzinga

14 May

Impact 4 · · Simply Wall St.

13 May

Impact 4 · · Simply Wall St.

12 May

Impact 4 · · biopharmadive.com
Impact 4 · · GlobeNewswire
Impact 4 · · PR Newswire
Impact 3 · · Simply Wall St.

6 May

Impact 4 · · Moby

5 May

Impact 4 · · PR Newswire
Impact 3 · · MarketBeat
Impact 3 · · Zacks
stockrow.com/RIGL · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com